ENHERTU®
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

Please join us for a discussion on

Expanding Possibilities With ENHERTU and DATROWAY

Faculty:

Noam Drazin, MD
Cedars-Sinai Medical Center
Los Angeles, CA

Program Details:

Tuesday, November 3, 2026
6:00 PM Central Time

Uchi
2817 Maple Avenue
Dallas, Texas
75201

RSVP:

Brandi Martin
brandi.martin@daiichisankyo.com
(405) 641-8753

By:

Tuesday, October 27, 2026

Please see Important Safety Information and accompanying full Prescribing Information, including Boxed WARNINGS for Interstitial Lung Disease/Pneumonitis and Embryo-Fetal Toxicity, and Medication Guide, available at this presentation, and at ENHERTUhcp.com, or scan QR code to the left.

Please see Important Safety Information, and accompanying full Prescribing Information, including Warnings and Precautions, and Medication Guide available at this presentation, and at DATROWAYhcp.com or scan QR code to the left.

The intended audience for this program is US healthcare professionals.

This program is being provided to you by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME-accredited and may not be used for CME accreditation. In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. Please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you may receive may be publicly disclosed.

If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that compliance with such requirements can be ensured.

Daiichi-Sankyo | AstraZeneca

ENHERTU® and DATROWAY® are registered trademarks of Daiichi Sankyo Company, Limited.
© 2026 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-MP-0640 02/26 US-107593